TRENDS

• Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015
  September 26, 2017

• Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?
  September 5, 2017

• Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
  August 22, 2017

• Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena
  August 18, 2017

• Top Drugs Jostling for Higher Share amid Tepid Market, Trulicity Overtakes Victoza in GLP Space: April-June
  August 7, 2017

• Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
  June 28, 2017

• Authorized Generics Solidifying Their Presence in Japan Gx Market
  June 16, 2017

• Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
  May 22, 2017

• Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
  April 10, 2017

• Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
  March 31, 2017

• As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
  March 23, 2017

• Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
  February 16, 2017

• Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
  February 7, 2017

• AGs Set to Break into 10 Billion Yen Territory in Japan
  November 14, 2016

• Gilead Stays Pat on Hep C Plan, Japan Chief Says Innovation Outstrips Re-Pricing Hit
  October 18, 2016

• Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
  September 26, 2016

• Sumitomo Dainippon Feeling Sense of Crisis about Operating Profit to Approach Zero; Will Offer Early Retirement and Cut Executive Compensation
  September 15, 2016

• Surprise Rule Change Pops Up Yet Again, This Time with Taltz
  September 5, 2016

• Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
  June 21, 2016

• Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020
  April 13, 2016

ページ